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Human renal cell carcinoma (RCC) is known to be largely resis-
tant to conventional chemotherapy, resulting in an extremely 
poor prognosis once the tumour has metastasized and is beyond
the reach of curative surgery (Mulders et al, 1997). Resistance to
chemotherapy has been explained by multiple mechanisms,
including the multidrug resistance phenotype (Baldini, 1997;
Mulders et al, 1997) or defects in apoptotic pathways (Hetts,
1998). Recent evidence indicates that CD95-mediated apoptosis
might also effectively determine the response of cancer cells to
cytotoxic drugs (Friesen et al, 1996; 1997; Strand et al, 1996;
Fulda et al, 1997; Krammer, 1997; Müller et al, 1997).
CD95 is a 45 kDa type I transmembrane receptor that confers an
apoptotic signal to sensitive cells upon trimerization by its ligand
CD95L, a type II membrane protein (Nagata, 1994). Following
activation of CD95-receptors, a death signal is generated that leads
to the activation of a cascade of cysteine proteases (caspases) and
finally to apoptosis (Kischkel et al, 1995). This apoptotic pathway
has originally been explored within the immune system only.
However, recent evidence indicates that the CD95 pathway is also
involved in drug-induced apoptosis of tumour cells (Krammer,
1997). Upregulation of CD95-ligand and/or -receptor has thus
been demonstrated in drug-sensitive leukaemias, hepatocellular
carcinomas and neuroblastomas upon treatment with various anti-
cancer drugs, and, most importantly, blocking of CD95 receptor
activation by antagonistic antibodies effectively inhibited drug-
induced apoptosis (Friesen et al, 1996; Fulda et al, 1997; Müller
et al, 1997). In contrast, drug-resistant leukaemia cells failed to
upregulate CD95-ligand expression and to activate the CD95-
pathway (Friesen et al, 1997). Remarkably, upregulation of CD95
receptor expression upon anticancer drug-treatment was observed
only in p53 wild-type hepatocellular carcinomas, indicating that
p53 might also be involved in the regulation of CD95-mediated
apoptosis (Müller et al, 1997; 1998). These observations suggested
that chemotherapeutic agents induce apoptosis via CD95-depen-
dent pathways and that resistance of tumours to chemotherapy
might also be related to deficient activation of the CD95 system.
Although CD95 receptor expression and CD95-mediated apop-
tosis have clearly been demonstrated in human RCCs (Caignard 
et al, 1996; Nonomura et al, 1996; Tomita et al, 1996; Horie et al,
1997; Miyake et al, 1998), the role of CD95-mediated apoptosis
for chemoresistance in human RCCs has yet to be established. 
The aim of the present investigation, therefore, was to study the
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Summary The pronounced resistance of human renal cell carcinoma (RCC) to anticancer-induced apoptosis has primarily been related to
the expression of P-glycoprotein and effective drug detoxification mechanisms. Because the CD95 system has recently been identified as a
key mediator of anticancer drug-induced apoptosis, we analysed the contribution of the CD95 system to chemotherapy-induced apoptosis in
four newly established RCC cell lines. Here, we demonstrate that all RCC cell lines expressed CD95-receptor and -ligand. Exposure to
agonistic anti-CD95 antibodies resulted in induction of apoptosis and significant (P < 0.05) reduction of cell number in three out of four cell
lines, indicating that the essential components for CD95-mediated apoptosis were present and functionally intact in the majority of these RCC
cell lines. Moreover, treatment of cultures with bleomycin or topotecan, a novel topoisomerase I inhibitor with little substrate affinity for P-
glycoprotein, led to induction of apoptosis and significant (P < 0.05) dose-dependent reduction of cell number in all RCC cell lines. Both
anticancer drugs also induced upregulation of CD95 ligand expression in all cell lines. Additionally, augmentation of CD95 receptor
expression was found in three RCC cell lines, including one p53-mutated cell line, whereas another p53-mutated cell line showed no or only
a weak CD95 receptor upregulation after exposure to topotecan or bleomycin, respectively. Despite this upregulation of CD95 receptor and
ligand, antagonistic antibodies directed against CD95 receptors or ligands could not inhibit induction of apoptosis by topotecan and bleomycin
in any cell line. Thus, although a functionally intact CD95 signalling cascade is present in most RCC cell lines, the anticancer drugs topotecan
and bleomycin that induce upregulation of CD95 receptor and ligand fail to effectively activate CD95-mediated apoptosis. This deficient
activation of CD95-mediated apoptosis might be an important additional factor for the multidrug resistance phenotype of human RCCs.
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induced apoptosis in human RCCs. To this end, we exposed newly
established human RCC cell lines of different histological types to
topotecan, a novel topoisomerase I inhibitor with little substrate
affinity for P-glycoprotein (Hendricks et al, 1992; Sorensen et al,
1995), or to the DNA-damaging antibiotic bleomycin, which has
been shown to act via the CD95 system (Müller et al, 1997).
MATERIALS AND METHODS
Cells and culture
All four cell lines used in this study were derived from typical
representatives of the clear cell (clearCa-3, -6, -17) and chro-
mophilic/papillary (chromphi-3) types of RCC (Gerharz et al,
1993; 1994; 1995; 1996). The cell lines were maintained with
Dulbeccos’s modified Eagle’s medium (DMEM, Gibco, FRG),
supplemented with 10% heat-inactivated fetal calf serum (FCS),
penicillin and streptomycin (= standard growth medium) and culti-
vated at 37°C in an atmosphere with 5% CO2.
Analysis of p53 mutations
Extraction of genomic DNA was performed using the QIAmp
Tissue Kit (Qiagen, FRG) according to the manufacturer’s
protocol. For amplification of p53 exons 5 to 8, the following
oligonucleotide primers were used: Exons 5 and 6: (forward) 5¢-
TTC CTC TTC CTG CAG TAC TC-3¢; (reverse) 5¢-ATG TGC
AAA CCA GAC CTC AG-3¢. Exons 7 and 8: (forward) 5¢-GTG
TTG TCT CCT AGG TTG GC-3¢; (reverse) 5¢-AAG TGA ATC
TGA GGC ATA AC-3¢. Each amplification reaction was carried
out in a total volume of 50 ml containing 200 ng of genomic DNA,
10 pmol of each primer, 10 nM of each dNTP, 2 U Taq polymerase
and PCR-reaction-buffer (Sigma, FRG). After an initial denatura-
tion step at 94°C for 2 min, 35 cycles of denaturation at 94°C for
30 s, annealing at 50°C for 40 s, and extension at 72°C for 1 min,
as well as a last delay at 72°C for 10 min, were performed. The
PCR-products were purified from surplus oligonucleotides using
Microspin S-300 columns (Pharmacia, FRG). The purified PCR-
products were prepared for automatic sequencing using the ABI-
Prism BigDye Terminator Cycle Sequencing Kit (Perkin Elmer,
FRG) according to the manufacturer’s protocol. Sequence analysis
was carried out with the sense (5¢) and the antisense (3¢) primer
using an ABI-Prism 310 sequencer (Perkin Elmer). p53 mutations
were verified by an independent PCR-amplification of genomic
DNA followed by a repeated sequencing.
RNA extraction
Total cellular RNA was isolated from RCC cell lines using either
the RNeasy kit (Qiagen) for the detection of CD95 receptor
mRNA, or the caesium chloride ultracentrifugation method for the
detection of CD95 ligand and p21 mRNA. RNA concentration was
measured by photometry at 260 nm.
RT-PCR analysis
For monitoring CD95 receptor and CD95 ligand expression,
reverse transcription was performed using an RT-kit (Stratagen,
FRG), 2 mg (CD95 receptor) or 5 mg (CD95 ligand) of total
cellular RNA and oligo(dT) (CD95 receptor) or random primer
(CD95 ligand) as RT-primer. The amplification mixture with a
final volume of 50 ml was composed as follows: 5 ml of the cDNA
template, 10 pM ml–1 (CD95 receptor) or 50 pM ml–1 (CD95
ligand) of the gene-specific primers, 200 mM (CD95 receptor) or
100 mM (CD95 ligand) of each dNTP and 1.5 U Taq-polymerase
(Sigma).
For the amplification of CD95 receptor, the following primers
were used (Cascino et al, 1995): (forward) 5¢ CAG AAC TTG
GAA GGC CTG CAT C 3¢; (reverse) 5¢ GGA CTT TGT CAC
CGT TAT TTA 3¢. These oligonucleotides amplified the trans-
membranous CD95 receptor (510 bp) as well as a splice variant
with a 63 bp deletion of the transmembranous region encoding the
soluble CD95 receptor (447 bp). The initial denaturation step at
94°C for 4 min was followed by 25 cycles of denaturation for 30 s,
annealing at 57°C for 30 s, extension at 72°C for 40 s, and a final
extension step at 72°C for 10 min. The PCR products were
separated on a 1.5% agarose gel and the ratio between both splice
variants was quantified by densitometry (Biometra, FRG) in three
independent experiments.
For the amplification of CD95 ligand, the following primers
were used (Peter et al. 1995): (forward) 5¢ ATA GGA TCC ATG
TTT CTG CTC TTC CAC CTA CAG AAG GA 3¢; (reverse) 5¢
ATA GAA TTC TGA CCA AGA GAG AGC TCA GAT ACG
TTG AC 5¢. The initial denaturation step at 94°C for 4 min was
followed by 35 cycles of denaturation for 1 min, annealing at 54°C
for 1 min, extension at 72°C for 1 min, and a final extension step
at 72°C for 10 min. Identity of the amplification products was
confirmed by direct sequencing (data not shown).
Northern blot analysis
Northern blot analysis was carried out for 20 mg RNA of each
sample under denaturating conditions with a 1% formaldehyde
gel. After transfer of the RNA to the Nylon membrane
(Amersham, FRG), the RNA was hybridized with a specific p21
cDNA probe generated by RT-PCR (primers: forward: 5¢ CAG
TGG ACA GCG AGC AGC TG 3¢; reverse: 5¢ ATC TGT CAT
GCT GGT CTG CC 3¢; 35 cycles of denaturation for 30 s,
annealing at 58°C for 30 s, extension at 72°C for 40 s). The DNA
was labelled by incorporation of 32P-dCTP using the oligo-labelling
kit (Pharmacia). Hybridization, stringent washing procedures and
radiography were carried out as previously described (Ramp et al,
1997). All experiments were done twice with different Nylon
membranes and the results obtained were reproducible.
Flow cytometric analysis
The expression of CD95 receptor and CD95 ligand was assessed
by fluorescence-activated cytometry carried out in a FACScan®
flow cytometer (Becton Dickinson, FRG). After 24 h in standard
growth medium, RCC cells were incubated for another 24, 48, and
72 h in growth medium supplemented with topotecan (1 mg ml–1)
or bleomycin (300 mg ml–1). As control, cells were maintained in
standard growth medium. 1 mg of the FITC-labelled monoclonal
antibodies (CD95 receptor-FITC: monoclonal IgG1 (mouse) anti-
body UB2, Immunotech, FRG; CD95 ligand-FITC: monoclonal
IgG2a (rat) antibody H11, Alexis, FRG) was added to each tube
with 1 ´ 105 cells in a final reaction volume of 200 ml and
incubated for 20 min at 4°C. Two washing steps were performed
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antibodies mouse-IgG1 (Immunotech) for CD95 receptor and rat-
IgG2a for CD95 ligand (Pharmingen, FRG) were used. All experi-
ments were done twice and the results obtained were reproducible.
Induction and quantification of apoptosis
1 ´ 104 cells were seeded in each chamber of 8-chamber slides
(Nunc, FRG). After 24 h, the cells were treated with topotecan
(0.01, 0.1, 1, or 10 mg ml–1) or bleomycin (3, 30 or 300 mg ml–1)
or CD95 receptor-activating CH11 antibody (0.5 mg ml–1,
Immunotech) (Natoli et al, 1995; Keane et al, 1996; O’Connell et
al, 1996; Strand et al, 1996) for another 48 h. For IFN-g pretreat-
ment, tumour cells were exposed to IFN-g (100 U ml–1; Biosource,
FRG) 24 h after seeding on 8-chamber slides. After another 48 h,
the growth medium was substituted by medium supplemented with
the CH11 antibody and cells were cultivated for another 48 h. As a
control, tumour cells were exposed to either standard growth
medium or growth medium supplemented with IFN-g
(100 U ml–1). The number of apoptotic cells per 1 ´ 103 cells was
determined by light microscopical counting of haematoxylin-eosin
(HE)-stained cells showing the typical morphological signs of
apoptosis, i.e. chromatin condensation and/or fragmentation into
apoptotic bodies. Counting of apoptotic cells was performed in
two independent experiments and the data presented are the mean
out of these experiments. Specific apoptotic death (SAD) was
calculated as the frequency of apoptotic cells after exposure to
topotecan or bleomycin or CH11 or CH11 + IFN-g minus the
frequency of apoptotic cells in standard growth medium.
Assessment of cell number
Tumour cells in the exponential growth phase were transferred to
microwell plates (Gibco) at 1 ´ 104 cells per well in 0.1 ml stan-
dard growth medium. After 24 h cells were exposed to topotecan
(0.01, 0.1, 1, or 10 mg ml–1) or bleomycin (3, 30, or 300 mg ml–1)
or CD95 receptor-activating CH11 antibody (0.5 mg ml–1,
Immunotech) in growth medium. As a control, tumour cells were
cultivated in standard growth medium. The plates were incubated
for another 48 h (topotecan or bleomycin) or 72 h (CH11) at 37°C
and 5% CO2. For IFN-g pretreatment, tumour cells were exposed
to IFN-g (100 U ml–1) for 48 h, and then incubated for another 72 h
in growth medium supplemented with CH11 (0.5 mg ml–1). As a
control for the effects of IFN-g on cell number, tumour cells were
exposed to IFN-g for 48 h and then incubated for another 72 h in
standard growth medium. The number of viable tumour cells was
then analysed using the colorimetric MTT assay (Mosman, 1983)
and measured on a spectrophotometric plate reader (Titertek
Multiscan, FRG) at 570 nm.
The data presented are the mean ± standard deviation from 24
replicate wells per microtitre plate and three independent experi-
ments per cell line. The data were statistically evaluated by an
analysis of variance with two independent factors. The 50%
inhibitory drug concentration (IC50 value) was statistically deter-
mined by SSPS (probit analysis).
Interactions between CH11 and topotecan were analysed by the
fractional inhibition method as follows: when expressed as the
fractional inhibition cell viability, additive inhibition produced
by both inhibitors (i) occurs when i1,2 = i1 + i2; synergism when i1,2
> i1 + i2; and antagonism when i1,2 < i1 + i2 (Webb, 1963).
Blockade of CD95 signalling by antibodies
To analyse the functional contribution of the CD95 system to anti-
cancer drug-induced apoptosis in RCC, we used antagonistic anti-
bodies directed against CD95 receptors (i.e. F(ab)¢2-anti-APO-1
antibody fragments made by PK’s laboratory) (Friesen et al, 1996;
Fulda et al, 1997; 1998; Müller et al, 1997), or antibodies binding
CD95 ligands (i.e. monoclonal 4H9 antibodies, Immunotech)
(Nakajima et al, 1998). Both antibodies competitively inhibit
binding of CD95 ligand to the CD95 receptor, resulting in a
blockade of the CD95 signalling pathway.
RCC cells were exposed to topotecan (1 mg ml–1) or bleomycin
(300 mg ml–1) as single agents or in combination with the F(ab)¢2-
anti-APO-1 antibody fragments (0.1 or 1 mg ml–1) or 4H9 anti-
bodies (0.1 or 1 mg ml–1). RCC tumour cells were then incubated
for 48 h and MTT assays were performed as described above.
RESULTS
Anticancer drugs induce apoptotic cell death in human
RCCs
Exposure to topotecan or bleomycin resulted in induction of apop-
tosis, as became evident from light microscopic inspection of cell
cultures (Figure 1). The determination of specific apoptotic death
(SAD) confirmed a dose-dependent increase of apoptotic cell
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Figure 1 Marked induction of apoptosis (arrows) in clearCa-6 cells after
exposure to topotecan (B) when compared to the control (A) (bar = 50 mm)death in all RCC cell lines (Figure 2), the response being most
pronounced in clearCa-6.
Induction of apoptosis was paralleled by a significant (P < 0.05)
dose-dependent reduction of cell number, the IC50 values ranging
from 0.12 mg ml–1 to 2.32 mg ml–1 for topotecan and from
430 mg ml–1 to more than 3000 mg ml–1 for bleomycin (Figure 2).
It is noteworthy that the effects of topotecan became evident
already at clinically relevant concentrations (< 1 mg ml–1) (Herben
et al, 1996), whereas the IC50 values of bleomycin were at least
100 times higher than the peak plasma concentration achievable
during chemotherapy in vivo (Scheithauer et al, 1986).
Anticancer drugs augment expression of CD95
receptors and ligands in human RCCs
As shown by RT-PCR (Figure 3) and flow cytometry (Figures 4
and 5), all RCC cell lines showed constitutive expression of CD95
receptor and ligand in standard culture medium.
Exposure to topotecan (1 mg ml–1) resulted in a time-dependent
increase in the expression of CD95 receptor and ligand in three out
of four cell lines, as revealed by flow cytometry (Figures 4 and 5).
The maximum expression was observed 72 h after exposure to
topotecan and only minor differences in the extent of induction
became evident between these cell lines. In contrast, clearCa-17
cells showed only a weak increase of CD95 ligand expression and
no concomitant upregulation of CD95 receptor expression
(Figures 4 and 5), although this cell line had also responded with
an increase of apoptotic cell death.
Exposure to bleomycin (300 mg ml–1) resulted in an augmenta-
tion of CD95-receptor and -ligand expression in all cell lines with
a maximal induction after 48 h (clearCa-3, -17, and chromphi-3)
or 72 h (clearCa-6) (Figures 4 and 5).
Anticancer drug-induced upregulation of CD95
receptor and ligand occurs in p53-mutated RCCs
Because p53 has been reported to be involved in the augmentation
of CD95 receptor expression in hepatocellular carcinomas after
exposure to anticancer agents (Müller et al, 1998), we additionally
defined the mutational status of p53 in our RCC cell lines.
Sequencing of p53 exons 5–8, which are the most commonly
affected hot-spot regions for p53 mutations in human cancer
(Harris and Hollstein, 1993; Reiter et al, 1993), revealed no
mutations in clearCa-3 and chromphi-3. In contrast, isolated point
mutations were found in clearCa-6 and clearCa-17 (Table 1).
Whereas clearCa-17 showed no (topotecan) or a weak
(bleomycin) increase of CD95 receptor expression, clearCa-6
responded with marked upregulation of CD95 receptor upon expo-
sure to both anticancer drugs despite p53 mutation. Moreover, upon
exposure to topotecan, clearCa-6 was still able to transcriptionally
activate the expression of p21 (Figure 6), known to be directly
regulated by p53 (El-Deiry et al, 1993; Waldman et al, 1995).
Anticancer drug-induced apoptosis is not mediated via
the CD95 pathway in human RCCs
The augmentation of CD95 receptor and/or ligand expression
observed in our RCC cell lines after treatment with topotecan or
bleomycin might suggest involvement of the CD95-system in
drug-induced cell death. To test this hypothesis, we competitively
inhibited the binding of CD95 ligand and hence CD95 receptor
activation either by antagonistic F(ab)¢2-anti-APO-1 antibody
fragments or by 4H9 anti-CD95 ligand antibodies. If the apoptotic
effects of anticancer drugs were actually mediated via the CD95-
system, simultaneous incubation of RCC cells with these anti-
bodies should block the effects of anticancer drugs.
The data obtained in these experiments are summarized in
Figure 7, showing that the reduction of cell number observed after
exposure to topotecan or bleomycin could not be blocked by anti-
bodies directed against CD95 receptors or ligands in any cell line.
These observations clearly show the existence of a CD95-
independent pathway for the action of topotecan and bleomycin
in all our RCC cell lines.
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Figure 2 Effects of topotecan or bleomycin on apoptosis and proliferation.
Exposure to topotecan or bleomycin resulted in an increase of specific
apoptotic death (SAD) as well as a significant (P < 0.05) dose-dependent
reduction of cell number in all RCC cell lines (vertical bars indicate standard
deviations)Essential components for CD95-mediated apoptosis
are present in human RCCs
Because the upregulation of CD95 receptor and ligand after expo-
sure to anticancer drugs was not followed by CD95-mediated cell
death, we hypothesized that the response to CD95 receptor activa-
tion might seriously be disturbed in our RCC cell lines. To test this
hypothesis, we used the agonistic anti-CD95 antibody CH11 to
confront RCC cell lines with a uniform pro-apoptotic signal.
As shown in Table 2, CD95 receptor activation by agonistic
CH11 antibodies resulted in an increase of specific apoptotic death
(SAD) in all RCC cell lines of the clear cell type, which was
followed by a significant (P < 0.05) reduction of cell number.
Differences between the extent of apoptotic response and reduc-
tion of cell number probably reflect differences in the onset
and kinetics of CD95-mediated apoptosis in our cell lines. After
pretreatment with IFN-g, which is known to increase CD95
receptor expression (Nonomura et al, 1996), CH11-triggered apop-
totic cell death was further augmented, as indicated by the increase
of SAD and the reduction of cell number (Table 2). In contrast,
chromphi-3 cells proved to be largely resistant against CD95
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Figure 3 Constitutive expression of CD95 receptor and ligand. (A) Using
primers simultaneously amplifying the transcripts of transmembranous and
soluble CD95 receptor, RT-PCR demonstrated coexpression of both CD95
receptor forms in all RCC cell lines with a predominance of the trans
membranous variant. (B) RT-PCR revealed CD95 ligand expression in all cell
lines (Concanavalin A-activated peripheral blood mononuclear cells (PBMC)
were used as positive control, NC = negative control)
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Figure 4 CD95 receptor expression after exposure to topotecan or
bleomycin. Exposure to topotecan (1 mg ml–1; thick line) or bleomycin
(300 mg ml–1; thick line) resulted in increase of CD95 receptor expression in
clearCa-3, -6, and chromphi-3 when compared with the control (medium
line). No increase of CD95 receptor expression was found in clearCa-17 after
exposure to topotecan (thin line = isotope control. Presented is the maximum
of CD95 receptor induction. Df describes the difference of mean fluorescence
intensities between drug-exposed tumour cells and the untreated control)
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Figure 5 CD95 ligand expression after exposure to topotecan or
bleomycin. Exposure to topotecan (1 mg ml–1; thick line) or bleomycin
(300 mg ml–1; thick line) resulted in increase of CD95 ligand expression
in all RCC cell lines when compared with the control (medium line) (thin
line = isotype control. Presented is the maximum of CD95 ligand induction.
Df describes the difference of mean fluorescence intensities between
drug-exposed tumor cells and the untreated control)receptor activation by CH11 antibodies, even after IFN-g pretreat-
ment. In conclusion, the essential components for CD95-mediated
cell death were present and functionally intact in all RCC cell lines
of the clear cell type, but not in the chromophilic RCC cell line.
Nevertheless, the upregulation of CD95 receptor and ligand
induced by topotecan or bleomycin was not sufficient for an
effective activation of CD95-mediated apoptosis.
Moreover, we asked whether anticancer drug-induced upregula-
tion of CD95 receptor expression might be exploited for CD95-
mediated apoptosis applying CH11 antibodies. To answer this
question, clearCa-3 and chromphi-3 cells (which had been least
responsive to CH11 antibodies as a single agent) were simultane-
ously exposed to both topotecan (1 mg ml–1) and CH11 (0.5 mg
ml–1) for 72 h. As shown in Figure 8, both cell lines responded
with a marked reduction of cell number. By fractional inhibition
analysis, it could be demonstrated that the effects of CH11 and
topotecan in combination were synergistic compared with either
agent alone.
DISCUSSION
Ample evidence exists that anticancer drugs exert their effects
through induction of apoptosis, irrespective of their primary intra-
cellular targets (Hickman, 1992). Only recently, CD95-triggered
apoptosis has been identified as a key mediator of chemotherapy
in leukaemias and some solid tumour types (Friesen et al, 1996;
Fulda et al, 1997; 1998; Müller et al, 1997). Vice versa, resistance
to anticancer drugs in leukaemias was shown to be associated with
defects of the CD95-system (Friesen et al, 1997). Up to now, the
pronounced resistance of human RCCs to chemotherapy had
primarily been related to effective drug elimination by transport
proteins such as P-glycoprotein (Baldini, 1997; Mulders et al,
1997) or to drug detoxification by the glutathione/glutathione-S-
transferase pathway (Mickisch et al, 1990). Investigations into the
function of the CD95 system in RCCs upon treatment with anti-
cancer drugs, therefore, could provide new insights into alternative
mechanisms of multidrug resistance in renal cancer and eventually
facilitate the design of novel therapeutic concepts.
The data presented here demonstrate that therapeutically rele-
vant concentrations of topotecan induced a marked, dose-depen-
dent increase of apoptosis and a significant (P < 0.05) reduction of
cell number in all our RCC cell lines. In accordance with previous
preclinical and clinical observations (Homma and Aso, 1994),
RCC cell lines, however, proved to be largely resistant to
bleomycin, showing only a minor reduction of cell number at
clinically relevant dose levels (≤ 3 mg ml–1).
Response to topotecan was paralleled by a marked increase in
the expression of CD95 receptor and ligand in three out of four
RCC cell lines. It was interesting to note, however, that an almost
corresponding upregulation of CD95 receptor and ligand could be
induced by bleomycin in all cell lines, although bleomycin had
shown far less pronounced effects on cell number when compared
to topotecan. These findings are in line with previous reports on
anticancer drug-induced upregulation of CD95 receptor and ligand
in other tumour models (Friesen et al, 1996; Müller et al, 1997;
Fulda et al, 1998). The upregulation of CD95 receptor and ligand
upon treatment with anticancer drugs, therefore, is a common
reaction pattern in a great variety of different human tumour types,
including RCCs.
However, the upregulation of CD95 receptor and ligand
observed in our RCC cell lines did not yet prove the actual func-
tionality of the CD95 system in chemotherapy-induced apoptosis.
1856 U Ramp et al
British Journal of Cancer (2000) 82(11), 1851–1859 © 2000 Cancer Research Campaign
Table 1 p53 status of exons 5 to 8 determined by DNA sequencing
Cell Wild-type (wt) and mutations (mt) of p53
lines
clearCa
3w t
6 mt: exon 8, codon 290: CGC (Arg) to CAC (His)
17 mt: exon 6, codon 213: CGA (Arg) to CTA (Leu)
chromphi
3w t
0 1 6 1 22 44 87 2 time (h)
p21
(2.3 kb)
GAPDH
clearCa-6
Figure 6 Upregulation of p21 expression after exposure to topotecan. After
exposure to topotecan (1 mg ml–1), Northern blot revealed increase of p21
expression in p53-mutated clearCa-6 cells, thereby suggesting functionally
intact p53 despite mutation. Hybridization with GAPDH demonstrated the
equality of RNA loaded in each lane
Table 2 Cell number and apoptotic response in RCC cell lines after exposure to CH11 (500 ng ml–1) or IFN-g (100 U ml–1) or IFN-g (100 U ml–1) + CH11
(500 ng ml–1)
CH11 IFN-g IFN-g + CH11
Cell BAD cell number SAD cell number SAD cell number SAD
lines (%) (% of the control) (%) (% of the control) (%) (% of the control) (%)
clearCa
3 2.6 88 ± 5 8.3 81 ± 4 3.3 42 ± 2 10.3
6 2.1 40 ± 4 32.1 79 ± 10 3.5 18 ± 1 48.9
17 1.7 62 ± 3 8.4 88 ± 6 1.2 11 ± 1*
chromphi
3 0.2 105 ± 2 0 93 ± 6 0.1 91 ± 3 0.6
Abbreviations: BAD = basal apoptotic death; SAD = specific apoptotic death; * marked response with less than 103 cells per chamber left (cf. Materials and
methods)Therefore, we used F(ab)¢2-anti-APO-1 antibody fragments or 4H9
anti-CD95 ligand antibodies, which are both known to block the
binding of CD95 ligand to its receptor, thereby preventing signal
transduction via the CD95 system (Friesen et al, 1996; Fulda et al,
1997; 1998; Müller et al, 1997; Nakajima et al, 1998). In these
experiments, the apoptosis induced by topotecan or bleomycin
could not be inhibited in any RCC cell line. Although not
explaining the underlying mechanisms, these results provide
convincing evidence that apoptosis induced by these anticancer
drugs is mediated via CD95-independent mechanisms in human
RCCs. The molecular effector pathways of chemotherapy-induced
apoptosis in RCCs, therefore, might differ from those in other
solid tumours like carcinomas of liver, colon, and lung, Ewing
sarcoma and neuroblastoma. In these tumour types, various anti-
cancer drugs including bleomycin have been shown to induce
apoptosis – at least in part – via the CD95-system (Fulda et al,
1997; 1998; Müller et al, 1997).
Little is known so far about the underlying mechanisms
prohibiting the activation of the CD95 system in RCCs despite
upregulation of CD95 receptor and ligand. However, our data
clearly demonstrate that the essential components of CD95-medi-
ated signal transduction are available and functionally intact in
three out of four RCC cell lines. Thus, we observed a marked
increase of apoptosis and a significant (P < 0.05) reduction of cell
number in all clear cell RCC cell lines upon CD95 receptor activa-
tion by agonistic anti-CD95 antibodies. Nevertheless, the levels of
anticancer drug-induced upregulation of CD95 receptor and ligand
were not sufficient for effective activation of CD95-mediated
apoptosis in these cell lines.
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Figure 7 CD95-antagonistic F(ab)´2-anti-APO-1 antibody fragments or
CD95 ligand-binding 4H9 antibodies did not inhibit topotecan- or bleomycin-
induced apoptosis. Combined exposure of F(ab)´2-anti-APO-1 antibody
fragments (0.1 or 1 mg ml–1) or 4H9 antibodies (0.1 or 1 mg ml–1) with
topotecan (1 mg ml–1) or bleomycin (300 mg ml–1) did not inhibit reduction of
cell number when compared with the effects of topotecan or bleomycin as
single agents. Exposure to F(ab)´2-anti-APO-1 antibody fragments (1 mg ml–1)
or 4H9 antibodies (1 mg ml–1) alone did not affect cell growth in any cell line.
CD95 receptor activation by agonistic CH11 antibodies (0.5 mg ml–1) resulted
in significant (P < 0.05) reduction of cell number in all RCC cell lines of the
clear cell type. F(ab)´2-anti-APO-1 antibody fragments completely inhibited
the reduction of cell number induced by CD95-agonistic CH11 antibodies
(0.5 mg ml–1) as exemplary shown in clearCa-6.
Figure 8 Synergistic enhancement of CH11-induced apoptosis in clearCa-3
and chromphi-3 by topotecan. Both cell lines were cultured in the presence of
CH11 (0.5 mg ml–1) or topotecan (1 mg ml–1) alone or in combination.
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clearCa-3 chromphi-3Interestingly in this context, p53 mutations have recently been
found to interfere with anticancer drug-induced and CD95-medi-
ated apoptosis, because wild-type p53 directly transactivates the
CD95 receptor (Owen-Schaub et al, 1995; Müller et al, 1998).
Consequently, the deficient activation of CD95-mediated cell death
in our RCC cell lines could be due to p53 mutations. Although p53
mutations are not very frequent in human RCCs (Reiter et al,
1993), mutant p53 was found in two of our RCC cell lines. In fact,
the missing activation of CD95-mediated apoptosis by anticancer
drugs might be explained by inadequately low levels of CD95
receptor upregulation in the p53-mutated cell line clearCa-17. In
contrast, however, the other p53-mutated RCC cell line (clearCa-6)
responded with a marked augmentation of CD95 receptor expres-
sion after treatment with anticancer drugs. This observation could
indicate the activation of p53-independent signalling pathways for
upregulation of CD95 receptors or might be due to functional
intactness of p53 despite mutation. The latter hypothesis was
supported by the failure to detect nuclear accumulation of p53
protein in clearCa-6 cells by immunocytochemical analysis (data
not shown). Thus, nuclear accumulation of p53 protein is an indi-
cator for confirmational changes of p53 protein, interfering with
both its function and degradation (Moll and Schramm, 1998).
Further evidence for functional intactness of mutant p53 in
clearCa-6 could be derived from topotecan-induced upregulation of
p21 expression, which is known to be transcriptionally regulated by
the p53 gene (El-Deiry et al, 1993; Waldman et al, 1995).
As outlined above, p53 inactivation by mutation could explain
the deficient activation of CD95-mediated apoptosis by anticancer
drugs in only one of our RCC cell lines. In most RCC cell lines,
however, the mechanisms that ultimately determine the response to
anticancer drug-induced upregulation of CD95 receptor and ligand
are not yet fully understood. This response will critically depend on
the balance of all the pro-apoptotic and anti-apoptotic programmes
acting along the CD95 signal transduction cascade (for review see
Schulze-Osthoff et al, 1998). In this context, it might be of partic-
ular relevance that two different types of CD95 signalling pathways
have been described only recently, one of which can effectively be
blocked by Bcl-2 or Bcl-xL overexpression (Scaffidi et al, 1998).
Collectively, our results provide convincing evidence that the
anticancer drugs topotecan and bleomycin induce upregulation of
CD95 receptors and ligands in human RCCs. Despite this upregula-
tion and despite the presence of a functionally intact CD95-
signalling cascade, CD95-mediated apoptosis is not effectively
activated by these agents. Nevertheless, topotecan and bleomycin
exploit alternative pathways also leading to apoptotic cell death.
Induction of apoptosis via these alternative pathways, however, is
far less effective in human RCCs when compared to the effects of
these drugs in other tumour types (Mitsui et al, 1995; Müller et al,
1997). These findings indicate that the deficient activation of
CD95-mediated apoptosis by anticancer drugs might additionally
contribute to the multidrug resistance phenotype of human RCCs.
Therefore, investigations into the mechanisms determining the
responsiveness to CD95-mediated apoptosis in human RCCs might
eventually facilitate the design of novel therapeutic concepts.
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